The short answer
Blincyto (Blinatumomab) is a type of immunotherapy called a bispecific antibody. It links immune T cells to leukemia cells by grabbing a marker (CD19) on the cancer and a marker on T cells at the same time, bringing them together so the T cells can kill the cancer. It is used to help treat some B-cell acute lymphoblastic leukemia (ALL), and is usually given as a continuous IV infusion through a small pump. Like all cancer medicines it can cause side effects; this page explains the common ones and the warning signs to report. It is educational only and not a substitute for your care team's advice.
Blincyto is the brand name; its generic name is blinatumomab.
It is a type of immunotherapy called a bispecific antibody — it links immune T cells to leukemia cells by grabbing a marker (CD19) on the cancer and a marker on T cells at the same time, bringing them together so the T cells can kill the cancer.
It is used to help treat some B-cell acute lymphoblastic leukemia (ALL).
It is usually given as a continuous IV infusion through a small pump.
Choose how you want to understand this
The full explanation.
What it is
Blincyto (Blinatumomab) is a cancer medicine. It is a type of immunotherapy called a bispecific T-cell engager. In plain terms, it links immune T cells to leukemia cells by grabbing a marker (CD19) on the cancer and a marker on T cells at the same time, bringing them together so the T cells can kill the cancer. You may see it called by its brand name, Blincyto, or by its generic name, blinatumomab. This page is a general explainer based on the National Cancer Institute's drug information; it does not replace the specific instructions your own care team gives you.
What cancers it treats
According to the National Cancer Institute, blinatumomab is approved to help treat some B-cell acute lymphoblastic leukemia (ALL). Whether it is the right choice for a particular person depends on the cancer type, its stage, test results such as biomarkers, and other treatments already tried. Your oncology team can explain why it was chosen for your situation.
How it's given
As a continuous IV infusion through a small pump. It is given as a nonstop infusion over several weeks using a portable pump, so the medicine is delivered steadily. Your team explains how to care for the pump and line. How much, how often, and for how long vary from person to person, so follow the exact schedule your care team gives you. If you miss an appointment or a dose, ask your team what to do rather than changing anything yourself.
Common side effects
Not everyone gets the same side effects, and some people have only mild ones. With blinatumomab, commonly reported effects include fever, headache, tiredness, low blood counts, and nausea. Many of these can be eased with supportive care. Tell your care team if you notice anything new, if a side effect is getting worse, or if it is making everyday life hard — they can often help, and knowing early usually makes problems easier to manage. Side effects do not tell you whether the medicine is working.
Serious warning signs
Some problems need prompt attention. Contact your care team right away (or use the emergency number they give you) if you notice a high fever or severe chills, confusion, trouble speaking, or unusual sleepiness, new shortness of breath, and dizziness or feeling faint. This is not a complete list, and it cannot tell you whether your own situation is an emergency — that is exactly why your team gives you personal instructions and a number to call. When in doubt, it is always reasonable to check in with them.
The bottom line
Blincyto (Blinatumomab) is one of many tools used in cancer care. Understanding what it is, how it is given, and what to watch for can make treatment feel less overwhelming and help you speak up early about side effects. Keep a simple list of anything you notice, bring your questions to appointments, and remember that your care team — not a website — is the right source for decisions about your treatment.
Words to know
Tap any term to see what it means.
Common questions
▸What is Blincyto?
Blincyto (Blinatumomab) is a type of immunotherapy called a bispecific antibody. It links immune T cells to leukemia cells by grabbing a marker (CD19) on the cancer and a marker on T cells at the same time, bringing them together so the T cells can kill the cancer. It is used to help treat some B-cell acute lymphoblastic leukemia (ALL).
▸How is Blincyto given?
It is usually given as a continuous IV infusion through a small pump. It is given as a nonstop infusion over several weeks using a portable pump, so the medicine is delivered steadily. Your team explains how to care for the pump and line. The exact schedule is set by your care team.
▸What are the common side effects of Blincyto?
Commonly reported side effects include fever, headache, tiredness, low blood counts, and nausea. Not everyone gets them, and many can be managed. Tell your care team about anything new or worsening.
▸Does Blincyto cure cancer?
That depends on the person, the cancer type, and its stage. For some people a medicine like this can control cancer for a long time or be part of a curative plan; for others the goal is to slow the cancer or ease symptoms. Your care team can explain the goal in your situation.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Test your knowledge
0 of 3 answered
This quiz checks understanding of educational content only. It is not medical advice. Open this quiz on its own page.
How this page was created
Cancer Explained uses AI to organize and translate information from the authoritative sources cited on each page. Automated checks review claims, citations, clarity, duplication, and potential safety concerns before publication. Our content is not currently reviewed by physicians unless a specific qualified reviewer is named on the page. Cancer Explained provides general education and should not replace advice from your healthcare team.
Editorial status: Editorial review complete — This page completed Cancer Explained's editorial checks (sources, safety, plain language, duplication). It has not been reviewed by a physician or other healthcare professional.
Human medical review: not completed. At this time, most Cancer Explained content has not been reviewed by a physician or other healthcare professional. Pages with documented human medical review identify the reviewer, credentials, and review date directly.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.